Sinovac Biotech, Total Revenue

Sinovac Biotech, (SVA) currently reports a total revenue of $1.9B as of December 2023. That compares with $20B in the prior-year period — down 90.2% year over year. That is below the Healthcare sector average of $110B. Use the charts on this page to explore Sinovac Biotech,'s total revenue history and peer comparisons.

Sinovac Biotech,'s total revenue decreased from $20B to $1.9B — a 90.2% year-over-year decrease (period ending December 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Sinovac Biotech,'s total revenue of $1.9B is lower than the Healthcare sector average of $110B. That is roughly 98.3% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Sinovac Biotech, reported $1.9B in total revenue as of December 2023. That compares with $20B in the prior-year period — down 90.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total revenue of $1.9B, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $110B. From there, open related valuation or income-statement pages for Sinovac Biotech,, and consider following SVA for alerts when major investors trade the stock.